Cancer-related fatigue (CRF) is one of the most prevalent symptoms patients with cancer experience, both during and after treatment. CRF is pervasive and affects patients' quality of life considerably. It is important, therefore, to understand the underlying pathophysiology of CRF in order to develop useful strategies for prevention and treatment. At present, the etiology of CRF is poorly understood and the relative contributions of the neoplastic disease, various forms of cancer therapy, and comorbid conditions (e.g., anemia, cachexia, sleep disorders, depression) remain unclear. In any individual, the etiology of CRF probably involves the dysregulation of several physiological and biochemical systems. Mechanisms proposed as underlying CRF include 5-HT neurotransmitter dysregulation, vagal afferent activation, alterations in muscle and ATP metabolism, hypothalamic-pituitary-adrenal axis dysfunction, circadian rhythm disruption, and cytokine dysregulation. Currently, these hypotheses are largely based on evidence from other conditions in which fatigue is a characteristic, in particular chronic fatigue syndrome and exercise-induced fatigue. The mechanisms that lead to fatigue in these conditions provide a theoretical basis for future research into the complex etiology of this distressing and debilitating symptom. An understanding of relevant mechanisms may offer potential routes for its prevention and treatment in patients with cancer.
Introduction
In a healthy person, fatigue occurs as an indispensable sensation that prompts the desire to rest. This response has probably evolved to protect against overexertion, which can lead to permanent tissue damage, or to promote healing. Fatigue associated with cancer or its treatment is distinct from the typical fatigue that most people experience as a result of normal daily life. Unlike typical fatigue, cancer-related fatigue (CRF) is disproportionate to exertion level and is not relieved by rest or sleep [1, 2] . CRF has been defined as a "persistent, subjective sense of tiredness related to cancer and cancer treatment that interferes with usual functioning" [3, 4] . CRF is extremely common, with most studies reporting prevalence rates above 60% and some studies reporting rates of up to 90% [5] . CRF is also persistent, in that it may be present at diagnosis, increase during therapy, and continue for months or years following the completion of therapy. CRF is frequently reported as the most distressing symptom associated with cancer and its treatment, even more so than pain, nausea, or vomiting. Thus, this symptom can have an immensely negative impact on patients' quality of life and daily activities. Until recently, fatigue in patients with cancer was underrecognized and undertreated because attention has been focused on other common symptoms, such as nausea and pain. This article reviews the current hypotheses and evidence for the etiology of CRF.
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What Is Fatigue?
Fatigue is a highly subjective multidimensional experience. Individuals may perceive fatigue as physical tiredness or exhaustion, a need for reduced activity, reduced motivation, and/or mental fatigue [6] . Much of what is known about fatigue focuses on physical fatigue as it relates to exercise (i.e., muscle response). From this perspective, fatigue is defined physiologically as the inability to maintain power output [7] , and is perceived as a sensation of weakness-even when the muscle is not being used-and/or a sense of greater effort required to accomplish a task. Additionally, fatigue includes psychological dimensions such as mental fatigue and reduced motivation. Mental fatigue can be expressed as a reduced capacity for attention, concentration, and learning, as well as a disturbance in short-term memory [8] .
The basic mechanisms of fatigue have been broadly categorized into two main components: peripheral and central. Peripheral fatigue, which occurs in the neuromuscular junctions and muscle tissues, results in the inability of the peripheral neuromuscular apparatus to perform a task in response to central stimulation. Mechanisms implicated in peripheral fatigue include a lack of ATP and the buildup of metabolic by-products. Central fatigue, which develops in the central nervous system (CNS), arises from the progressive failure to transmit motor neuron impulses [9] . Central fatigue has been defined as difficulty in the initiation or maintenance of voluntary activities [10] . Central fatigue thus manifests as "a failure to complete physical and mental tasks that require self-motivation and internal cues, in the absence of demonstrable cognitive failure or motor weakness" [11, 12] .
The sensation of fatigue may arise from peripheral signals mediated by afferent nerves in the muscles or closely related structures (e.g., tendons and joints) and/or by activation of central pathways in the cerebral cortex. Conversely, an individual's perception of effort appears to be linked more to the effort required to generate force than to the magnitude of the force exerted. The perception of effort may involve a central mechanism of signaling from the motor cortex to the primary somatosensory cortex [13, 14] . However, the relationship between the sensations of effort and fatigue has not yet been elucidated.
Mechanisms Underlying Cancer-Related Fatigue
Fatigue has been studied in normal (exercise) conditions and in the context of chronic diseases, including chronic fatigue syndrome and rheumatoid arthritis. However, there are limitations to extrapolating results of these studies to CRF because different etiologic factors are likely to be involved.
Serotonin Dysregulation
One hypothesis proposed to explain CRF is that cancer and/ or cancer treatment causes an increase in brain serotonin (5-HT) levels and/or upregulation of a population of 5-HT receptors, leading to reduced somatomotor drive, modified hypothalamic-pituitary-adrenal (HPA) axis function, and a sensation of reduced capacity to perform physical work [15] . 5-HT has numerous functions, including control of appetite, sleep, memory, learning, temperature regulation, mood, behavior, cardiovascular function, muscle contraction, endocrine regulation, and depression, and there is increasing evidence for a role for 5-HT in the genesis of central fatigue. In particular, research in exercise-induced fatigue and chronic fatigue syndrome implicates 5-HT dysregulation in the etiology of central fatigue.
5-HT Levels and Central Fatigue
Exercise increases the concentration of tryptophan, the precursor of 5-HT, in the brain, leading to increased synthesis of 5-HT by some neurons. The increased concentration of 5-HT could result in physical and mental fatigue during prolonged exercise [16] [17] [18] . Studies in patients with chronic fatigue syndrome have demonstrated raised plasma levels of free tryptophan, which could potentially lead to high central 5-HT levels [19, 20] . Animal studies have shown that sustained exercise increases 5-HT levels in the hypothalamus and brain stem [21] ; however, the site(s) at which 5-HT is elevated in humans during exercise is not well understood. The rate-limiting step for synthesis of 5-HT in the brain is the transport of tryptophan into the brain. Tryptophan and branched-chain amino acids (BCAAs) compete for entry into the brain via a transporter [22] . During exercise, BCAAs are taken up by muscle cells. One hypothesis suggests that increased levels of central 5-HT during exercise are caused by a reduction in circulating BCAAs, which allows more tryptophan to enter the brain [23, 24] . In addition, exercise increases the concentration of plasma free fatty acids that displace tryptophan from albumin, thus generating more available unbound tryptophan in plasma [25] . Animal studies have shown that 5-HT concentrations increase during sustained exercise, reaching a maximum at the point of fatigue [21, 26] . From studies in humans, Blomstrand and colleagues [27] [28] [29] and Mittleman and colleagues [30] reported that supplementation with BCAAs before and during exercise was associated with improved physical and mental performance. Other studies in humans, however, have failed to find a link between BCAA supplementation and delayed onset of physical fatigue or increased exercise capacity [31] [32] [33] [34] [35] .
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Oncologist ® Alterations in central serotonergic transmission are associated with fatigue during exercise. Animal studies have shown that administration of 5-HT produced a dose-related decrease in running endurance [36] , while a 5-HT antagonist improved performance [26] . In several human studies, administration of selective serotonin reuptake inhibitors (SSRIs) has been shown to reduce the capacity to perform exercise. In two separate studies using healthy subjects, administration of the SSRI paroxetine (20 mg) prior to cycling exercise was associated with earlier exhaustion compared with placebo [33, 37] . Similar outcomes were observed with fluoxetine administration [38] . Conversely, Strachan and colleagues [39] showed that acute administration of paroxetine had no effect on exercise performance. Although considerable evidence suggests a role for 5-HT metabolism and/or neurotransmission in fatigue associated with various conditions, other investigators have shown that central 5-HT concentrations do not influence CRF [40, 41] .
Changes in 5-HT Receptors and Fatigue
Changes in 5-HT receptors may also contribute to fatigue. Patients with chronic fatigue syndrome may have enhanced serotonergic responses, possibly due to upregulation and/or hypersensitivity of postsynaptic 5-HT 1A receptors in the hypothalamus [42] [43] [44] . Cleare and colleagues [45] have also reported evidence of decreased 5-HT 1A receptor numbers or affinity in chronic fatigue syndrome. Other evidence suggests a disruption of the interaction between the HPA axis and the serotonergic system in chronic fatigue syndrome [46] . This disrupted interaction may arise either from decreased responsiveness of the 5-HT 1A receptors responsible for controlling the HPA axis at the hypothalamic level or from reduced pituitary responsiveness [47] . Treatment with 5-HT 3 receptor antagonists, such as granisetron and ondansetron, which relieve fatigue associated with chronic fatigue syndrome and chronic liver disease, may be a promising intervention for CRF [48] [49] [50] [51] .
Dysregulation of Central 5-HT Metabolism and
Cancer-Related Fatigue Dysregulation of central 5-HT metabolism or function may be a contributing factor in CRF. There is evidence that proinflammatory cytokines, such as tumor necrosis factor (TNF)-α, can influence 5-HT metabolism. Evidence suggests the existence of a feedback loop between TNF-α and central 5-HT [52] in which peripherally synthesized TNF-α causes an increase in 5-HT release into the synaptic space [53] . In addition, TNF-α can increase 5-HT transporter function, resulting in increased clearance of 5-HT from the synaptic space [54, 55] . Conversely, 5-HT can decrease TNF-α synthesis. The feedback loop in the CNS may become dysregulated in patients with pathologic conditions or in response to cancer therapies [52] .
Possible means by which systemic cytokines could influence the CNS include activation of peripheral afferent nerves (see below for further discussion) and the production of neuromediators, such as prostaglandins, at the blood-brain interface [56] . In addition, proinflammatory cytokines, such as interleukin (IL)-1β, interferon (IFN)-α, IFN-γ, and TNF-α, may directly or indirectly stimulate indoleamine 2,3-dioxygenase to alter 5-HT metabolism [57] .
HPA-Axis Dysfunction and Cancer-Related Fatigue
Another potential etiology of fatigue is the disturbance of the HPA axis. Low levels of circulating cortisol have been observed in patients with chronic fatigue syndrome [47] . The HPA-axis dysfunction hypothesis proposes that cancer, and/ or cancer treatment, alters the function of the HPA axis, resulting in endocrine changes that cause or contribute to fatigue.
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In fact, animal experiments have shown that different types of stress induce different changes in HPA-axis activity. Physical and/or psychological stresses tend to increase hypothalamic CRH expression [58] [59] [60] , while chronic inflammation (i.e., biological stress) tends to reduce central CRH synthesis and release [61] . Animal models of a variety of conditions, including rheumatoid arthritis, systemic lupus erythematosus, and cholestatic liver disease, support the possible relationship among chronic inflammatory response, defective CRH synthesis/release, and fatigue [61] [62] [63] [64] .
In humans, fatigue has also been linked to reduced HPA-axis function and hypocortisolemia in multiple clinical conditions, including cancer, chronic fatigue syndrome, and rheumatoid arthritis. Despite the frequent coexistence of depression and fatigue in patients with cancer, depression is actually associated with hypercortisolemia [65, 66] . By contrast, in conditions manifesting with fatigue, such as chronic fatigue syndrome, mild hypocortisolemia has been observed [47] . Although the specific HPA-axis dysfunction in chronic fatigue syndrome is unclear, possible explanations include defective central CRH release, downregulation of CRH receptors in response to chronic stress, and reduced cortisol output [67] [68] [69] .
Some evidence indicates altered HPA-axis function in CRF. As with chronic fatigue syndrome, some studies have indicated that CRF may be associated with reduced cortisol output [70, 71] . Bower and colleagues [70] measured morning (8-10 a.m.) serum cortisol levels in women who survived breast cancer (mean time from diagnosis, ≤5.5 years). Women who experienced fatigue had significantly lower serum cortisol levels than those who did not report fatigue. In another study, the same investigators applied the Trier Social Stress Test to breast cancer survivors (mean time since diagnosis, 8.4 years) to induce activation of the HPA axis [72] . The results showed that women with fatigue had a significantly blunted response to the stressor, as measured by salivary cortisol levels, compared with women without fatigue (Fig. 2) [71] . Currently, possible correlations between high cortisol levels and CRF are inconclusive [73, 74] . Discrepancies between studies may be due to differences in patient groups, type of sample, and timing of sample collection [73] . The diurnal rhythm, rather than overall cortisol levels, may be more significant with respect to the disturbances in HPA-axis function seen in patients with cancer, as discussed in the following section.
At present, the relationship among cancer, fatigue, and dysregulation of the HPA axis is unclear. Changes in the HPA axis may be caused by a number of different factors relevant to neoplastic disease. Proinflammatory cytokines, such as IL-1, IL-6, and TNF-α, are potent stimulators of the HPA axis [57] . Cortisol levels are controlled by the interaction of 5-HT with the HPA axis at the level of the hippocampus, hypothalamus, and pituitary, where stimulation of 5-HT 1A receptors signals the release of CRH, ADH, and ACTH [75] . In addition, there may be direct suppression of the HPA axis by cancer therapies, such as glucocorticoids, radiotherapy, and some forms of chemotherapy [76] [77] [78] . In turn, HPA-axis function influences immune cell development, maturation, and trafficking, and cytokine production, including production of proinflammatory cytokines [73, 79] . Cortisol, for example, has a suppressive effect on proinflammatory cytokine production, and hence reduced cortisol levels allow cytokine levels to rise [80] . Although the current hypothesis proposes that HPA-axis disruption may cause CRF, there is also the possibility that comorbid conditions, such as sleep disturbance, may cause changes in the HPA axis [81] . The role of comorbid conditions in CRF is likely to be an important area for future research.
Circadian Rhythm Disruption
Another potential process by which cancer may cause fatigue is circadian rhythm disruption. Circadian rhythms are endogenous genetically-and physiologically-based patterns that are controlled by the body's "biological clock." These rhythms typically have a 24-hour cycle and are sensitive to The Oncologist ® many environmental (e.g., alterations in light and dark) and psychological factors (e.g., stress, anxiety, and illness).
Several alterations in circadian function have been demonstrated in patients with cancer. These include changes in endocrine rhythms (e.g., cortisol, melatonin, and prolactin secretion), metabolic processes (e.g., temperature and circulating protein levels), the immune system (e.g., levels of circulating leukocytes and neutrophils), and rest-activity patterns [73, [82] [83] [84] [85] [86] [87] [88] [89] . Types of rhythm alteration include diminished amplitude, phase shifts, period changes, and erratic peaks and troughs. Patients with advanced cancer tend to demonstrate the greatest rhythm alterations [84, 86, 88] .
Research examining possible links between circadian rhythms and CRF has focused on cortisol secretion rhythms and rest-activity patterns. Bower and colleagues [73] investigated the change in salivary cortisol levels between the morning on awakening and the late evening in women who survived breast cancer (mean time since diagnosis, >6 years). The subgroup of patients with fatigue was found to have a significantly flatter diurnal cortisol slope than the subgroup without fatigue. Further investigation showed that patients with fatigue tended to have a slower decline in cortisol levels over the course of the day, and that increased fatigue severity correlated with flatter slope plots.
Sleep disorders are common in patients with cancer [90] and may arise from altered rest-activity rhythms. Berger [91] and Mormont and colleagues [85, 92] measured relative levels of activity in patients with breast or colorectal cancer using actigraphy. Both research groups showed an inverse relationship between fatigue and activity levels during the day and a positive relationship between fatigue and restless sleep at night. A relationship between the quality of 24-hour rest-activity rhythms and fatigue was also observed: patients with inconsistent and/or dampened circadian rhythms tended to experience greater fatigue than patients with better defined rhythms [93] [94] [95] [96] . For example, Roscoe and colleagues [96] demonstrated a significant correlation between more consistent patterns of sleep and activity (measured over a 72-hour period using actigraphy) and lower fatigue scores in patients with breast cancer (Fig. 3) . Furthermore, changes in fatigue between chemotherapy cycles correlated with changes in the circadian rest-activity rhythm. Notably, this study found that the association between fatigue and circadian disruption was independent of the presence of depression, even though depression correlated with disrupted circadian rhythm.
The causes of cancer-related circadian dysregulation may include genetic factors, psychosocial, environmental, and behavioral influences, and effects of the tumor on host rhythm regulation [84, 86] . Altered neuroimmunologic responses could mediate associations among cancer (and its treatments), circadian rhythms, and fatigue [95] ; however, the cause-and-effect relationship is likely to be complex. Diurnal changes in cortisol are known to change the number and function of immune cells, which could affect the suppression of proinflammatory cytokine production [80, 97] . In addition, flattened cortisol rhythms in patients with breast cancer have been shown to be associated with altered immune function [89, 98] .
Muscle Metabolism/ATP Dysregulation
Patients' perceptions of CRF are often described as feelings of "weakness" and "lack of energy." Such subjective feelings are likely to relate, at least in part, to peripheral fatigue (i.e., the muscles have a reduced capacity for contractile response). The negative correlation between physical function and CRF has been confirmed by objective measurement of physical performance [99, 100] . One hypothesis to explain this aspect of CRF is that cancer and/or its treatment leads to a defect in the mechanism for regenerating ATP in skeletal muscle, thereby compromising the ability to perform mechanical tasks (Fig. 4) [15] . www.TheOncologist.com ATP is the major source of energy for contraction of skeletal muscle. Hydrolysis of the high-energy phosphate bonds in ATP releases energy; in normal circumstances, the ATP is then replenished. Depletion or failure to replenish ATP compromises muscle function. Studies investigating muscle fatigue in patients with chronic fatigue syndrome showed reduced oxidative muscle metabolism [101] , depleted cellular ATP associated with a dysregulated 2ʹ,5ʹ-oligoadenylate synthetase/RNase L pathway [102] , and impaired synthesis of ATP [103] . In addition, reduced skeletal muscle concentrations of ATP and creatine phosphate have been noted in patients with chronic renal failure, who often report fatigue and weakness as symptoms of their illness [104] .
Evidence is limited for the disruption of ATP metabolism in the muscles of patients with cancer. Patients with cancer often have reduced energy intake, due to alterations in appetite and adverse effects of treatment (e.g., anorexiacachexia), which may limit ATP repletion. Increased levels of uncoupling proteins, accompanied by reduced levels of ATP, have been reported in the skeletal muscle of patients with cancer [105, 106] . Furthermore, it has been proposed that patients with cancer, particularly those with anorexiacachexia, have altered muscle protein metabolism [107] .
Studies investigating ATP depletion provide further evidence of an association between altered ATP metabolism and fatigue. A randomized clinical trial in patients with advanced non-small-cell lung cancer showed that ATP infusions improved muscle strength as well as some aspects of quality of life, such as tiredness [108] . In addition, Forsyth and colleagues [102] conducted a randomized, double-blind, placebo-controlled, crossover study to test the hypothesis that administration of nicotinamide adenine dinucleotide (NAD), a key coenzyme in the formation of ATP, could alleviate symptoms in patients with chronic fatigue syndrome. NAD, administered orally in its reduced form (NADH), decreased fatigue and improved quality of life [102] . Depending on the extent of ATP depletion in CRF, NAD administration may be a promising therapeutic strategy.
Vagal Afferent Nerve Activation
Vagal afferent nerves may also play a role in the development of fatigue. The vagal nerve comprises a large proportion of afferent fibers that communicate signals from the viscera to the brain stem, and it supplies efferent parasympathetic fibers to visceral organs such as the heart and stomach. The vagal afferent nerve hypothesis proposes that cancer and/or its treatment causes a peripheral release of neuroactive agents that activate vagal afferent nerves, leading to suppression of somatic muscle activity and induction of "sickness behavior."
Several animal studies have provided evidence of a vagosomatic inhibitory reflex. The earliest report of such an effect was by Schweitzer and Wright [109] , who showed that electrical stimulation of the central terminus of the vagal nerve in cats was associated with a reduction in the knee-jerk reflex. Subsequent animal studies showed that activation of vagal afferent nerves to the lungs or to the abdomen caused reflex inhibition of somatomotor activity, including reflex activation of skeletal muscles and exerciseinduced electromyogram activity [110] [111] [112] [113] [114] [115] [116] . Other studies have shown that a variety of substances, such as 5-HT, cytokines, and prostaglandins, can stimulate vagal afferent nerves [117] [118] [119] [120] . The purpose of the abdominal vagal afferent suppression of somatic muscle activity is unknown; 
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Vagal afferent nerves may also mediate the induction of "sickness behavior" by peripheral cytokines. Cytokineinduced "sickness behavior" occurs in response to infection and includes symptoms such as fatigue, increased sleep, malaise, listlessness, inability to concentrate, subjective feelings of poor memory, fever, and decreased appetite. Animal studies have shown that "sickness syndrome" can be induced by intraperitoneal injection of lipopolysaccharide or IL-1β [123] [124] [125] [126] . Further animal studies have shown that the vagal nerve mediates induction of IL-1β production in the brain stem, hippocampus, and hypothalamus in response to intraperitoneal injections of IL-1β [127] . Given the potential involvement of the HPA axis in the genesis of fatigue, induction of cytokines in the hypothalamus is of particular interest. One might hypothesize that CRF is a result of a reflex inhibition of skeletal muscle activity caused by the secretion of proinflammatory cytokines and/ or 5-HT in peripheral areas where vagal afferent nerves terminate. How vagal afferent activation might contribute to the long-term persistence of CRF is unclear.
Cytokine Dysregulation
Proinflammatory cytokines, such as TNF-α and IL-1β, are implicated in many of the mechanisms proposed for the etiology of fatigue associated with cancer and various illnesses [56] . Experimental or therapeutic administration of proinflammatory cytokines is known to induce "sickness behavior" [128] [129] [130] [131] [132] [133] . In particular, TNF has been shown to be associated with alterations in CNS neurotransmission, leading to behavioral changes such as lethargy and anorexia [134] . IFN-α, which is used in the treatment of a number of malignancies, is also associated with fatigue [135, 136] .
Cancer and its treatment (chemotherapy, surgery, radiotherapy, biologic therapies) are associated with increases in plasma levels of cytokines, especially TNF-α, IL-1β, and IL-6 [137] [138] [139] [140] . One published clinical study has examined possible correlations between serum cytokine levels and fatigue in patients with cancer [141] . No correlation was found between IL-6, IL-1β, or TNF-α and fatigue, even though a correlation between IL-6 levels and flu-like symptoms was observed in patients with breast cancer undergoing chemotherapy with paclitaxel. In that study, measurements were made at only three time points during one treatment cycle, rather than at regular intervals throughout the cycle, which could explain the lack of correlation between serum cytokine levels and fatigue. Support for the role of cytokines in the etiology of fatigue comes from reports of elevated TNF-α and IL-6 levels in patients with chronic fatigue syndrome [129, 142, 143] . Furthermore, monoclonal antibody treatment to block proinflammatory cytokine activity has been shown to ameliorate fatigue associated with Castleman's disease and rheumatoid arthritis, and could serve as a new intervention for CRF [144] [145] [146] .
Contribution of Comorbid Conditions Associated with Cancer-Related Fatigue
CRF often occurs as part of a cluster of symptoms and is accompanied by conditions that are likely to contribute to the development of fatigue. The most common of these symptoms include anemia, cachexia, depression, and sleep disorders.
Anemia
Anemia (a hemoglobin level of <12 g/dl) may occur as a result of either neoplastic disease or cancer treatment. It is identified by the National Comprehensive Cancer Network as one of the treatable factors that may contribute to CRF [3] . The incidence of anemia in patients with cancer varies by type, stage, and duration of the disease and its treatment [147] . Although occurring less frequently than fatigue, anemia is a common complication of myelosuppressive chemotherapy [147] . On average, over one third of patients become anemic after three cycles of chemotherapy [148] . The cause of anemia associated with cancer is multifactorial. Bleeding, hemolysis, bone marrow infiltration, and nutritional deficiencies may all contribute to the development of anemia in patients with cancer. In addition, inflammatory cytokines, such as TNF-α, IL-1, IL-6, and IFN-γ, inhibit erythropoiesis, which leads to decreased production of erythrocytes, resulting in anemia and fatigue [149] [150] [151] .
Many studies have demonstrated a relationship between anemia and fatigue [148, [152] [153] [154] [155] . Hemoglobin function may be altered by changes in the membrane transport characteristics of erythrocytes, such as changes in potassium, chloride, and magnesium ion fluxes, in response to neoplastic disease or cancer therapy. Support for this hypothesis comes from the fact that the lifespan of erythrocytes is reduced in cancer-related anemia [156] and from evidence that erythrocyte magnesium levels may play a role in chronic fatigue syndrome [157] . The mechanism by which anemia or hemoglobin dysfunction might cause fatigue in patients with cancer is unknown; however, hypoxia-related impairment of organ function has been suggested [158] .
www.TheOncologist.com Cachexia Cachexia is a wasting disease that involves loss of both adipose tissue and skeletal muscle mass, leading to anorexia, weight loss, fatigue, impaired function, and shortened survival time. Cancer cachexia is common, affecting approximately 50% of all patients with cancer and up to 85% of patients with certain cancers, such as gastric and pancreatic cancer [159, 160] . The etiology of cancer cachexia is complex and involves not only a reduction in nutrient intake, but also tumor-induced metabolic alterations, including protein catabolism and reduced protein synthesis in skeletal muscle. The tissue catabolism occurring in cachexia is thought to be mediated by cytokines (TNF-α and IL-6) [161] [162] [163] and tumor catabolic products, such as lipid-mobilizing factor and proteolysis-inducing factor [162] . Proinflammatory cytokines may also induce the release of CRH, which has a powerful anorexigenic effect [164] . Potential therapies aimed at preventing skeletal muscle wasting, such as anticatabolic agents, may help alleviate CRF.
Depression
Though less prevalent than fatigue, depression is common in patients with cancer. Many studies have reported strong correlations between the incidence of depression and fatigue in patients with cancer [128, 132, [165] [166] [167] [168] [169] [170] . Some evidence suggests a common etiology for depression and fatigue. For example, depression is known to be a predisposing factor for the development of chronic fatigue syndrome [171] . In contrast, other investigators have concluded that CRF and depression are independent conditions with patterns that differ over time. In a study of patients undergoing radiotherapy, fatigue was found to increase over the course of treatment, whereas depression decreased [172] . Neither condition was found to be predictive of the other. As previously discussed, several investigations have noted distinctions between depression and fatigue with regard to disrupted rest-activity rhythms [96] , 5-HT dysfunction [40, 41] , and altered HPA-axis activity [65, 66] . Hence, it is currently unclear whether fatigue and depression arise through a common pathway.
Sleep Disorders
Strong correlations have been reported between fatigue and sleep disorders in patients with cancer [90] . Sleep disorders may arise via several of the mechanisms discussed above, including HPA-axis and circadian rhythm disruption, serotonin metabolism alterations, and changes in cytokine expression. The HPA axis plays a key role in the regulation of sleep. Likewise, CRH may affect several aspects of sleep, including depth of sleep, slow-wave sleep, rapid eye movement (REM) sleep, and waking. Studies in both humans and animals have shown that CRH increases electroencephalograph frequency and decreases slow-wave sleep, resulting in lighter sleep and greater wakefulness [173, 174] . In healthy individuals, excess cortisol reduces REM sleep. However, results from studies in patients with Addison's disease have suggested that some degree of cortisol secretion is necessary to initiate and maintain REM sleep [81, 175] . CRH is also associated with waking, suggesting that sleeping and waking depend on a balance between endogenous cortisol levels and CRH suppression [176] .
As previously mentioned, dysregulation of HPA-axis function and cortisol release have been linked with sleep disorders. Cancer therapy has also been associated with dysregulation of the HPA axis and hypocortisolemia. For example, patients with breast cancer receiving chemotherapy show significant differences in cortisol, melatonin, and serotonin levels compared with both disease-free individuals and patients with cancer who are not receiving treatment [177, 178] . Furthermore, there is considerable evidence supporting the involvement of cytokines in sleep disorders. Several studies have demonstrated that the cytokines TNF-α and IL-6 are elevated in disorders associated with excessive daytime sleepiness, such as sleep apnea, narcolepsy, and idiopathic hypersomnia [81, 179, 180] . Overexpression of cytokines, including IL-1, IL-6, and TNF-α, by cancer cells and as part of the immunologic response has been demonstrated in patients with cancer and in their response to cancer therapy [181] . Similarly, there is evidence supporting the involvement of IL-6 and TNF-α in the development of fatigue. This emerging area of research connecting sleep disorders with CRF is discussed in greater depth in an accompanying article [90] .
Summary
The etiology of CRF is multifactorial and most likely involves the dysregulation of several interrelated physiological, biochemical, and psychological systems, thus presenting considerable challenges for patients, researchers, and clinicians. The disorder, or combination of disorders, causing CRF may differ among individuals, phases of disease, and types of treatment. Several mechanisms for the development of CRF have been proposed, which may aid in the development of therapies to combat this debilitating symptom. Future research needs to focus on understanding the interrelationships among the various cancer-related symptoms and the similarities and differences in fatigue experienced in different conditions.
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